Aurolife Pharma Completes USFDA Inspection Of Raleigh Manufacturing Facility
· Business · Business Standard
Aurolife Pharma has successfully concluded a United States Food and Drug Administration inspection at its manufacturing plant located in Raleigh, North Carolina. The facility underwent a routine regulatory assessment to ensure compliance with quality and safety standards. Following the inspection, the company confirmed that the process has been completed. The report does not specify if the USFDA issued any observations or findings regarding the site's operations. Aurolife Pharma is a subsidiary of the Indian pharmaceutical company Aurobindo Pharma.
Why it matters
Successful USFDA inspections are critical for maintaining export access to the US market, which is a major revenue driver for Indian pharmaceutical companies. Any adverse findings could lead to regulatory delays or import restrictions for drugs manufactured at the Raleigh site.
Read the original report — Business Standard
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.